Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664010 | 1.00 | LMNA (0.55) | LMNAKMT2AALDH1A1HTTNPSR1 | |
| SCHEMBL3657913 | 0.94 | MAPT (0.50) | LMNAKMT2ANPY2RMAPTPOLB | |
| SCHEMBL3714846 | 0.88 | KCNH2 (0.52) | — | |
| SCHEMBL3658072 | 0.88 | KMT2A (0.47) | LMNAKMT2AHTTNPSR1HPGD | |
| SCHEMBL2981578 | 0.85 | NPY2R (0.44) | LMNANPY2RMAPT | |
| SCHEMBL4122445 | 0.83 | KMT2A (0.55) | LMNAKMT2AALDH1A1HTTNPSR1 | |
| SCHEMBL3664126 | 0.81 | KMT2A (0.52) | LMNAKMT2AALDH1A1MAPTPOLB | |
| SCHEMBL3663393 | 0.80 | KMT2A (0.56) | LMNAKMT2AALDH1A1HTTNPSR1 | |
| SCHEMBL2978680 | 0.79 | NPY2R (0.39) | NPY2R | |
| SCHEMBL3656235 | 0.76 | CYP2C19 (0.55) | LMNAKMT2ASMN1; SMN2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212314-A1 | IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050200-A1 | IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099243-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099243-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLCO1B1, SLCO1B3 | LMNA 2430/4885KMT2A 2020/4885ALDH1A1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.